profit from every $100 of sales.
$0$100
Ascentage Pharma Group International
$15.00-3.23% today
-56.3% in 1 year
1-year low $13.481-year high $34.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Ascentage Pharma Group International sold, what it kept, and what it did with the cash.
Sales went from CN¥210 million in 2022 to CN¥574 million in 2025, with -CN¥1.24 billion of profit last year.
SalesProfit
Ascentage Pharma Group International vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ascentage Pharma Group International | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Ascentage Pharma Group International's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 210 | 222 | 981 | 574 | |
| 188 | 191 | 952 | 525 | |
| -850 | -873 | -370 | -1,198 | |
| -771 | -744 | -238 | -1,095 | |
| -883 | -926 | -405 | -1,243 | |
| -13.40 | -13.12 | -5.36 | – | |
| 89.5% | 86.2% | 97.0% | 91.5% | |
| -405.2% | -393.1% | -37.7% | -208.6% | |
| -421.0% | -417.0% | -41.3% | -216.5% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,830 | 2,500 | 2,618 | 3,964 |
| Cash | 1,476 | 1,069 | 1,237 | 2,464 |
| Total debt | 1,793 | 1,796 | 1,668 | 1,980 |
| Total liabilities | 2,422 | 2,430 | 2,344 | 2,629 |
| 409 | 60 | 264 | 1,324 | |
| 66 | 71 | 76 | – | |
| -29.9% | -35.6% | -13.5% | -28.3% | |
| -216.1% | -1,532.1% | -153.5% | -93.8% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -654 | -726 | -111 | -1,174 | |
| 237 | 57 | 24 | 28 | |
| -891 | -783 | -136 | -1,202 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| 27 | 6 | 0 | 9 | |
| 22 | 32 | 21 | 21 |
Valuation
- –
- –
- –
- 9.3×
- 16.3×
- –
- –
- -12.9%
- -13.3%
- 0.0%
Profitability
- 91.5%
- -208.6%
- -216.5%
- -196.0%
- -33.7%
- -36.3%
- -123.6%
- -31.0%
- -51.5%
- 196.6%
Growth
- +39.9%
- –
- −785.9%
- –
- +53.8%
Financial health
- -0.4×
- 1.49
- 49.9%
- -46.3×
- 1.79
- 1.77
- 0.14
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 958
Top 14%of 889
Bottom 8%of 987
What analysts expect
- Average price target
- $45.33
- Range
- $40.00 – $51.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 24, 2026 | -0.65 | -0.83 | +21.7% |
| Aug 20, 2025 | -0.96 | – | – |
| Mar 27, 2025 | -1.00 | 0.02 | −6,134.6% |
| Aug 22, 2024 | 0.31 | – | – |
| Jun 30, 2024 | 0.30 | – | – |
| Dec 31, 2023 | -1.02 | – | – |
| Aug 21, 2023 | -0.81 | – | – |
| Jun 30, 2023 | -3.15 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
22No pass
Philip Fisher
53No pass
Peter Lynch
59No pass
Joel Greenblatt
2No pass
Charlie Munger
35No pass
Terry Smith
47No pass
Questions about Ascentage Pharma Group International
Is Ascentage Pharma Group International a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ascentage Pharma Group International AI analysis
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. It is in Biotechnology.
Does Ascentage Pharma Group International pay a dividend?
No. Ascentage Pharma Group International does not pay a dividend at the moment; in 2025 it returned $9.04 million to shareholders by buying back its own shares.
Is Ascentage Pharma Group International stock halal?
Yes. Ascentage Pharma Group International passes our halal screen: its business is permitted and its debt is 21% of its market value, under the 30% limit. How we check
How has Ascentage Pharma Group International stock done over the past year?
Down 56.3% over the past twelve months, to $15.00. It traded between $13.48 and $34.30 and is 56.3% below its high.
Who are Ascentage Pharma Group International's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Ascentage Pharma Group International's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.